CoChat

Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial

Iseki, K., Arima, H., Kohagura, K., Komiya, I., Ueda, S., Tokuyama, K., Shiohira, Y., Uehara, H., Toma, S., on behalf of the Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group, Tomiyama, N., Arima, H., Chinen, S., Tokashiki, K., Hirano-Nakasone, A., Nohara, C., Ueda, S., Ueda, S., Kohagura, K., Toma, S., Tana, T., Higa, A., Yamazato, M., Ishida, Y., Tokuyama, K., Nagayoshi, N., Miyagi, S., Asato, T., Kobayashi, R., Shiohira, Y., Yonaha, T., Uezu, Y., Kuwae, N., Nakasato, S., Oshiro, Y., Nashiro, K., Asato, T., Katsuren, H., Kagawa, H., Naika-Geka, K., Higa, T., Ikema, M., Akamine, K., Nishihira, M., Jahana, M., Imai, C., Yonaha, T., Ikemura, M., Uechi, M., Yamazato, M., Yoshihara, K., Arakaki, M., Iha, K., Afuso, H., Kiyuna, S., Shiroma, K., Miyara, T., Itokazu, M., Naka, T., Naka, S., Yamaguchi, E., Uechi, Y., Kowatari, T., Yamada, H., Yoshi, S., Sunagawa, H., Tozawa, M., Uechi, M., Adaniya, M., Afuso, H., Uehara, H., Miyazato, H., Sakuda, C., Taminato, T., Uchima, H., Nakasone, Y., Funakoshi, T., Nakazato, M., Nagata, N., Miyazato, S., Katsuren, H., Miyagi, T., Hirano, H., Iwashiro, K., Sunagawa, T., Yoshida, H., Oshiro, Y., Shimabukuro, T., Oura, T., Henzan, H., Kyan, I., Maeshiro, S., Wake, T., Tagawa, S., Inoue, T., Tokashiki, T., Ishii, H., Miyagi, S., Takishita, S., Saito, S., Shimizu, K., Ohya, Y., Barzi, F. · 2013 · Nephrology Dialysis Transplantation
Cited by 99

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Hypertension is a major risk factor for death and cardiovascular disease (CVD) in patients undergoing chronic haemodialysis (HD), but there is uncertainty surrounding the effects of blood pressure (BP) lowering on this high-risk patient group. METHODS: In a multicenter, prospective, randomized, open-label, blinded-endpoint trial, 469 patients with chronic HD and elevated BP (140-199/90-99 mmHg) were assigned to receive the angiotensin receptor blockade (ARB) olmesartan (at a dose of 10-40 mg daily; n = 235) or another treatment that does not include angiotensin receptor blockers and angiotensin-converting enzyme (ACE) inhibitors (n = 234). The primary outcomes were the following: (i) composite of death, nonfatal stroke, nonfatal myocardial infarction and coronary revascularization and (ii) all-cause death. RESULTS: During a mean follow-up of 3.5 years, the mean BP was 0.9/0.0 mmHg lower in the olmesartan group than in the control group (not significant). A total of 68 patients (28.9%) in the olmesartan group and 67 patients (28.6%) in the control group had subsequent primary composite endpoints [hazard ratio (HR) in the olmesartan group 1.00, 95% confidence interval (CI) 0.71-1.40, P = 0.99]. All-cause deaths occurred in 38 patients (16.2%) in the olmesartan group and 39 (16.7%) in the control group (HR, 0.97; 95% CI, 0.62-1.52, P = 0.91). Olmesartan did not alter the risks of serious adverse events. CONCLUSIONS: BP-lowering treatment with an ARB did not significantly lower the risks of major cardiovascular events or death among patients with hypertension on chronic HD. (Cochrane Renal Group Prospective Trial Register number CRG010600030).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfs590

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 99

Metadata

Authors
Iseki, K., Arima, H., Kohagura, K., Komiya, I., Ueda, S., Tokuyama, K., Shiohira, Y., Uehara, H., Toma, S., on behalf of the Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group, Tomiyama, N., Arima, H., Chinen, S., Tokashiki, K., Hirano-Nakasone, A., Nohara, C., Ueda, S., Ueda, S., Kohagura, K., Toma, S., Tana, T., Higa, A., Yamazato, M., Ishida, Y., Tokuyama, K., Nagayoshi, N., Miyagi, S., Asato, T., Kobayashi, R., Shiohira, Y., Yonaha, T., Uezu, Y., Kuwae, N., Nakasato, S., Oshiro, Y., Nashiro, K., Asato, T., Katsuren, H., Kagawa, H., Naika-Geka, K., Higa, T., Ikema, M., Akamine, K., Nishihira, M., Jahana, M., Imai, C., Yonaha, T., Ikemura, M., Uechi, M., Yamazato, M., Yoshihara, K., Arakaki, M., Iha, K., Afuso, H., Kiyuna, S., Shiroma, K., Miyara, T., Itokazu, M., Naka, T., Naka, S., Yamaguchi, E., Uechi, Y., Kowatari, T., Yamada, H., Yoshi, S., Sunagawa, H., Tozawa, M., Uechi, M., Adaniya, M., Afuso, H., Uehara, H., Miyazato, H., Sakuda, C., Taminato, T., Uchima, H., Nakasone, Y., Funakoshi, T., Nakazato, M., Nagata, N., Miyazato, S., Katsuren, H., Miyagi, T., Hirano, H., Iwashiro, K., Sunagawa, T., Yoshida, H., Oshiro, Y., Shimabukuro, T., Oura, T., Henzan, H., Kyan, I., Maeshiro, S., Wake, T., Tagawa, S., Inoue, T., Tokashiki, T., Ishii, H., Miyagi, S., Takishita, S., Saito, S., Shimizu, K., Ohya, Y., & Barzi, F.
Venue
Nephrology Dialysis Transplantation
Published
2013-01-25
Volume
28
Issue
6
Pages
1579-1589
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2147048637
Cited by
99
References
6
FWCI
6.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. https://app.cochat.ai/papers/10.1093/ndt/gfs590
The paper
Iseki, K., Arima, H., Kohagura, K., Komiya, I., Ueda, S., Tokuyama, K., Shiohira, Y., Uehara, H., Toma, S., on behalf of the Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group, Tomiyama, N., Arima, H., Chinen, S., Tokashiki, K., Hirano-Nakasone, A., Nohara, C., Ueda, S., Ueda, S., Kohagura, K., . . . Barzi, F. (2013). Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfs590

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.